Modifying miRs for effective reprogramming of fibroblasts to cardiomyocytes
© 2024 The Author(s)..
Reprogramming scar fibroblasts into cardiomyocytes has been proposed to reverse the damage associated with myocardial infarction. However, the limited improvement in cardiac function calls for enhanced strategies. We reported enhanced efficacy of our miR reprogramming cocktail miR combo (miR-1, miR-133a, miR-208a, and miR-499) via RNA-sensing receptor stimulation. We hypothesized that we could combine RNA-sensing receptor activation with fibroblast reprogramming by chemically modifying miR combo. To test the hypothesis, miR combo was modified to enhance interaction with the RNA-sensing receptor Rig1 via the addition of a 5'-triphosphate (5'ppp) group. Importantly, when compared with unmodified miR combo, 5'ppp-modified miR combo markedly improved reprogramming efficacy in vitro. Enhanced reprogramming efficacy correlated with a type-I interferon immune response with strong and selective secretion of interferon β (IFNβ). Antibody blocking studies and media replacement experiments indicated that 5'ppp-miR combo utilized IFNβ to enhance fibroblast reprogramming efficacy. In conclusion, miRs can acquire powerful additional roles through chemical modification that potentially increases their clinical applications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Molecular therapy. Nucleic acids - 35(2024), 2 vom: 11. März, Seite 102160 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Xinghua [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
5′-triphosphorylation |
|---|
| Anmerkungen: |
Date Revised 19.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.omtn.2024.102160 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369855329 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369855329 | ||
| 003 | DE-627 | ||
| 005 | 20240319233222.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240318s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.omtn.2024.102160 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1336.xml |
| 035 | |a (DE-627)NLM369855329 | ||
| 035 | |a (NLM)38495845 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Xinghua |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Modifying miRs for effective reprogramming of fibroblasts to cardiomyocytes |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 19.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Author(s). | ||
| 520 | |a Reprogramming scar fibroblasts into cardiomyocytes has been proposed to reverse the damage associated with myocardial infarction. However, the limited improvement in cardiac function calls for enhanced strategies. We reported enhanced efficacy of our miR reprogramming cocktail miR combo (miR-1, miR-133a, miR-208a, and miR-499) via RNA-sensing receptor stimulation. We hypothesized that we could combine RNA-sensing receptor activation with fibroblast reprogramming by chemically modifying miR combo. To test the hypothesis, miR combo was modified to enhance interaction with the RNA-sensing receptor Rig1 via the addition of a 5'-triphosphate (5'ppp) group. Importantly, when compared with unmodified miR combo, 5'ppp-modified miR combo markedly improved reprogramming efficacy in vitro. Enhanced reprogramming efficacy correlated with a type-I interferon immune response with strong and selective secretion of interferon β (IFNβ). Antibody blocking studies and media replacement experiments indicated that 5'ppp-miR combo utilized IFNβ to enhance fibroblast reprogramming efficacy. In conclusion, miRs can acquire powerful additional roles through chemical modification that potentially increases their clinical applications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 5′-triphosphorylation | |
| 650 | 4 | |a IFNβ | |
| 650 | 4 | |a MT: Non-coding RNAs | |
| 650 | 4 | |a RNA modification | |
| 650 | 4 | |a cardiomyocytes | |
| 650 | 4 | |a fibroblasts | |
| 650 | 4 | |a innate immune signaling | |
| 650 | 4 | |a miRs | |
| 650 | 4 | |a reprogramming | |
| 700 | 1 | |a Baksh, Syeda S |e verfasserin |4 aut | |
| 700 | 1 | |a Pratt, Richard E |e verfasserin |4 aut | |
| 700 | 1 | |a Dzau, Victor J |e verfasserin |4 aut | |
| 700 | 1 | |a Hodgkinson, Conrad P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular therapy. Nucleic acids |d 2012 |g 35(2024), 2 vom: 11. März, Seite 102160 |w (DE-627)NLM222953810 |x 2162-2531 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2024 |g number:2 |g day:11 |g month:03 |g pages:102160 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.omtn.2024.102160 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2024 |e 2 |b 11 |c 03 |h 102160 | ||